A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile

Archives of Internal Medicine

Volumn 166, Issue 22, 2006, Pages 2518-2524

  Kazakova, Sophia V ^a,b   Ware, Kim ^c   Baughman, Brittany ^b   Bilukha, Oleg ^b   Paradis, Anne ^c   Sears, Stephen ^c   Thompson, Angie ^a   Jensen, Bette ^a   Wiggs, Lois ^a   Bessette, Jemelie ^d   Martin, James ^d   Clukey, Judy ^c   Gensheimer, Kathleen ^d   Killgore, George ^a   McDonald, L Clifford ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c Maine General Medical Center   (United States)

^d Maine Department of Health and Human Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEPHALOSPORIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; GATIFLOXACIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LEVOFLOXACIN; MOXIFLOXACIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE TRANSMISSION; DRUG USE; EPIDEMIC; FEMALE; GENE DELETION; HOSPITAL; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSYCHOSIS; PULSED FIELD GEL ELECTROPHORESIS; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTI-INFECTIVE AGENTS; CASE-CONTROL STUDIES; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; DISEASE OUTBREAKS; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MIDDLE AGED; RESIDENTIAL FACILITIES; RISK FACTORS;

EID: 33845480746     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.22.2518     Document Type: Article

References (25)

1. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis. 1998;26:1027-1034.
2. Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.
3. Kyne L, Hamel MB, Polavaram R, Kelly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346-353.
4. Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol. 2002;40:3470-3475.
5. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18:247-263.
6. Soehn F, Wagenknecht-Wiesner A, Leukel P, et al. Genetic rearrangements in the pathogenicity locus of Clostridium difficile strain 8864 - implications for transcription, expression and enzymatic activity of toxins A and B. Mol Gen Genet. 1998;258:222-232.
7. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol. 2004;53:887-894.
8. Barbut F, Decre D, Lalande V, et al. Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol. 2005;54:181-185.
9. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis. 2005;40:265-272.
10. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis. 2004;38:646-648.
11. Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38:640-645.
12. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis. 2003;9:730-733.
13. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433-2441.
14. Johnston JA, Wagner DP, Timmons S, Welsh D, Tsevat J, Render ML. Impact of different measures of comorbid disease on predicted mortality of intensive care unit patients. Med Care. 2002;40:929-940.
15. Klaassen CH, van Haren HA, Horrevorts AM. Molecular fingerprinting of Clostridium difficile isolates: pulsed-field gel electrophoresis versus amplified fragment length polymorphism. J Clin Microbiol. 2002;40:101-104.
16. Rupnik M, Brazier JS, Duerden BI, Grabnar M, Stubbs SL. Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology. 2001;147:439-447.
17. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol. 2004;42:1933-1939.
18. National Committee for Clinical Laboratory Standards. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. 6th ed. Wayne, Pa: National Committee for Clinical Laboratory Standards; December 31, 2004. Approved standard M11-A6.
19. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-485.
20. McDonald LC. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol. 2005;26:672-675.
21. Muto CA, Pokrywka M, Shutt K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 2005;26:273-280.
22. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004;171:33-38.
23. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41:1254-1260.
24. Jonkers D, Stobberingh E, Stockbrugger R. Omeprazole inhibits growth of gram-positive and gram-negative bacteria including Helicobacter pylori in vitro. J Antimicrob Chemother. 1996;37:145-150.
25. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989-2995.